The molecular epidemiology of oncoproteins: Serum p53 protein in patients with asbestosis

Chest

Volumn 109, Issue 3 SUPPL., 1996, Pages 22S-26S

  Hemminki, Kari ^a   Partanen, Riitta ^a   Koskinen, Heikki ^b   Smith, Steven ^d   Carney, Walter ^c   Brandt Rauf, Paul W ^d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^c Oncogene Science   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PLASMA PROTEIN; PROTEIN P53;

ADULT; AGED; ASBESTOSIS; CONFERENCE PAPER; DELETION MUTANT; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ASBESTOSIS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MUTATION; TIME FACTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029919030     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Lane DP. p53 and human cancers. Br Med Bull 1994; 50:582-99
2. Iggo R, Gatter K, Bartek J, et al. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675-79
3. Vahakangas KH, Samet JM, Metcalf RA, et al. Mutations in p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992; 339:576-80
4. Bodner SM, Minna JD, Jensen SM, et al. Expression of mutant p53 in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992; 7:743-49
5. Quinlan DC, Davidson AG, Summers CL, et al. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52:4828-31
6. Sozzi G, Miozzi M, Pastorini U, et al. Genetic evidence for an independent origin of multiple preneoplastic and neoplastic lung lesions. Cancer Res 1995; 55:135-40
7. Smith S, Marion M-J, Luo J-C, et al. Mutant p53 protein as a biomarker of chemical carcinogenesis in humans. Occup Environ Med (in press)
8. Luo J-C, Zehab R, Anttila S, et al. Detection of serum p53 protein in lung cancer patients. J Occup Med 1994; 36:155-60
9. Partanen R, Koskinen H, Oksa P, et al. Serum oncoproteins in asbestosis patients. Clin Chem (in press)
10. Brandt-Rauf PW, Smith S, Hemminki K, et al. Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 1992; 50:881-85 .
11. Brandt-Rauf PW, Luo J-C, Carney WP, et al. Detection of increased amounts of the extracellular domain of the c-erbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans. Int J Cancer 1994; 56:383-86
12. Partanen R, Hemminki K, Brandt-Rauf PW, et al. Serum levels of growth factor receptors, EGFR and neu in asbestosis patients: a follow-up study. Int J Oncol 1994; 4:1025-28
13. Partanen R, Hemminki K, Koskinen H, et al. The detection of increased amounts of the extracellular domain of the epidermal growth factor receptor in serum during carcinogenesis in asbestosis patients. J Occup Med 1994; 36:1324-28
14. Fontanini G, Fiore L, Bigini D, et al. Levels of p53 antigen in the serum of non-small cell lung cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement. Int J Oncol 1994; 5:553-58
15. Cattoret G, Pileri S, Parravicini C, et al. Antigen unmasking on formalin-fixed, paraffin-embedded tissue sections. J Pathol 1993; 171:83-98
16. Rusch V, Klimstra D, Linkov I, et al. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and expression precedes squamous cell carcinoma development. Cancer Res 1995; 55:1365-72
17. Luo J-C, Neugut AI, Garbowski G, et al. Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. Cancer Lett 1995; 91:235-40
18. Winter SF, Minna JD, Johnson BE, et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52:4168-74
19. Schlichtholz B, Tredaniel J, Lubin R, et al. Analysis of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions of p53 protein. Br J Cancer 1994; 69:809-16